CPT 87580: Mycoplasma pneumoniae Direct Nucleic Acid Probe Test
CPT code 87580 represents a direct nucleic acid probe test for Mycoplasma pneumoniae, a bacterial pathogen responsible for atypical respiratory infections. This molecular diagnostic procedure is used in clinical laboratories to identify bacterial nucleic acid and inform clinical management and public health surveillance. Nationally, molecular testing for respiratory pathogens is a key component of infectious disease diagnostics and can influence antibiotic stewardship and patient isolation decisions.
Key payers included in the analysis are Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of the clinical context for 87580, typical sites of service, and the role this test plays in laboratory diagnosis of respiratory infections. The publication also covers reimbursement benchmarks, coding considerations, and recent policy updates affecting laboratory molecular diagnostics when available.
This report provides operational and billing context for laboratory managers, coding professionals, and policy analysts seeking a national perspective on CPT code 87580. Data not available in the input is noted where applicable, and the focus remains on clinical utility, payer coverage landscape, and administrative considerations relevant to this molecular diagnostic assay.
Customize your policy alerts
Sign up for cpt 87580 policy alerts
Get alerted when payer policies referencing 87580 are released or updated.
Monitor payer policy activity
Billing Code Overview
CPT code 87580 describes a laboratory test that detects Mycoplasma pneumoniae using a direct nucleic acid probe technique. The procedure involves a laboratory analyst performing a molecular assay to identify the presence of bacterial nucleic acid specific to Mycoplasma pneumoniae.
Service Type: Infectious disease molecular diagnostic test
Typical Site of Service: Laboratory or hospital clinical laboratory
Data not available in the input.